Researchers analyzed 180 adults admitted to two private psychiatric inpatient facilities in Australia. The cohort's median age was 50.5 years and 52% were female. Kidney function, reported as estimated glomerular filtration rate (eGFR) using the CKD‑EPI 2021 equation, split the group into three strata: ≥90 mL/min/1.73 m2 (106 participants), 60–90 mL/min/1.73 m2 (61 participants), and <60 mL/min/1.73 m2 (13 participants). The primary biomarker was plasma p-tau217, measured on the Simoa platform, with neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as secondary biomarkers. Data indicated that, compared with the ≥90 group, plasma p-tau217 concentrations were 36% higher in the 60–90 group (β = 0.42; P = .008) and 116% higher in the <60 group (β = 1.05; P = .002). These comparisons were generated from multivariable models adjusted for age, body mass index, and sex. The authors reported these elevations in a cohort explicitly free of diagnosed neurological disease.
The study team also modeled kidney function continuously rather than only by strata. Modeled results showed plasma p-tau217 fell as eGFR rose: specifically, p-tau217 was 9.5% lower per 10 mL/min/1.73 m2 higher eGFR (95% CI: 3.3%, 15.4%). That gradient implies even modest declines in kidney filtration — above the conventional chronic kidney disease threshold — associate with measurable increases in plasma tau phosphorylation markers. The authors used linear regression with adjustment for demographic and anthropometric covariates; the biomarker analyses were performed blinded to clinical data.
Plasma NfL and GFAP were elevated in the group with eGFR <60 mL/min/1.73 m2. The differences for these markers did not reach statistical significance in the 60–90 mL/min/1.73 m2 stratum when compared with the ≥90 reference group. In other words, mild reductions in kidney function were associated with higher p-tau217 but did not produce the same clear pattern for NfL or GFAP in this cohort. The authors reported these differing profiles directly from their Simoa platform measurements and statistical contrasts.
Investigators adjusted their multivariable linear regression for three covariates: age, BMI, and sex. Biomarker assays were conducted blinded to clinical information. The analysis is cross-sectional; it compared biomarker concentrations across predefined eGFR categories and also assessed eGFR as a continuous predictor. The sample size distributions were 106 (≥90), 61 (60–90), and 13 (<60), which the authors present in their results table. The preprint reports beta coefficients, confidence intervals, and P values for the key contrasts; those statistics underpin the stated percentage increases in plasma p-tau217 across kidney function strata.
Current fixed diagnostic thresholds for plasma p-tau217 do not account for kidney function, the study team noted. Their data suggest that modest reductions in eGFR — even when above the CKD diagnostic cutoff of 60 mL/min/1.73 m2 — are associated with higher plasma p-tau217 and could therefore increase false positive rates if thresholds are applied uniformly. The investigators recommend that kidney function across its full range be incorporated into p-tau217 reference ranges and clinical interpretation. They argued, based on the observed continuous relationship between eGFR and p-tau217, that adjusting thresholds or applying eGFR‑stratified reference intervals may reduce both false positive and false negative classifications in settings where plasma tau biomarkers are used for diagnostic or screening purposes.
This report is a preprint and has not undergone peer review; the authors explicitly state it should not be used to guide clinical practice. The study used a cross-sectional design in a specific population—adults admitted with psychiatric disorders—and excluded participants with diagnosed neurological disease. The sample included only 13 participants with eGFR <60 mL/min/1.73 m2, which limits precision for the lowest-function stratum. The source did not report longitudinal follow-up, cause-effect inference, or external validation in community or memory-clinic populations. The preprint does not provide details on assay analytical variability or on whether specific clinical thresholds for p-tau217 were recalibrated within the study. Data are available upon reasonable request to the authors, and the investigators declared institutional ethics approval (The Royal Melbourne Hospital Human Research Ethics Committee, MH2020.142). Remaining unanswered questions documented by the authors include how to operationalize eGFR‑adjusted reference ranges for p-tau217, whether the same effect applies across different assay platforms or clinical populations, and what eGFR cutpoints — if any — should prompt alternative diagnostic interpretation. The authors also disclosed competing interests as reported in the preprint.